9 PRP Kit and Protocol Failures That Flatten Results
What goes wrong when a kit is poorly chosen or the protocol is inconsistent?
Two very different failures look identical from the patient's chair, and telling them apart is most of the job. A mismatched kit fails at the biology, handing you a preparation sitting near baseline when hair protocols generally work from three to six times whole blood, while an inconsistent protocol fails at reproducibility, so the same kit gives you a different product every visit. You almost never see either one as an adverse event, you see it at month four as a patient with no visible change and no record that explains why.
| What You're Diagnosing | Poorly Chosen Kit | Inconsistent Protocol |
|---|---|---|
| Failure point | Separation biology | Reproducibility |
| Usual cause | Chemistry tuned for another tissue target | Draw volume, anticoagulant ratio and spin drift |
| What the patient sees | Flat result at month four | Flat result at month four |
| The correction | Match the device, then count platelets | Fix the values, log every session |
A kit whose separation chemistry was built for a different tissue target can hand back a platelet concentration factor near baseline instead of the three to six times whole blood hair protocols generally work from, so the session delivers a fraction of the intended dose with no visible clue in the tube.
What happens to platelet yield when a kit's separation chemistry does not match the intended concentration?
Separation is a density problem before it's a clinical one. Platelets aren't one population but two, the lighter ones below about 1.046 specific gravity and the heavier ones above about 1.055, straddling the leukocyte band at roughly 1.050, so every kit is really a device for putting a boundary at one chosen density. Get that boundary wrong and you won't see it, because the concentrate is the same shade of straw yellow either way.
- Gel barrier position: Fixed at manufacture, so you can't adjust it at the bedside.
- Reported recovery: Yields average fifty to eighty percent across preparation methods.
- Automated systems: Typically land nearer forty to sixty percent recovery.
- Spin force: Well under 100 to 300 g leaves platelets among the red cells.
Reported platelet yields average between fifty and eighty percent across preparation methods and nearer forty to sixty percent for commercial automated systems, so the only way to know your own number is a blood count on the whole-blood sample and on the finished concentrate.
How do inconsistent draw volumes and spin settings change the dose a patient actually receives?
Dose is a multiplication, and inconsistency attacks every term in it. Draw 8 mL on one visit and 15 mL on the next and you've nearly doubled the delivered dose before you've touched the centrifuge, which is why total platelet dose in billions is the honest unit rather than a concentration multiple. Your patients move the number too, since someone at 160,000 platelets per microlitre and someone at 380,000 in the next chair get very different treatments from an identical protocol.
Drawing 8 mL on one visit and 15 mL on the next is close to a twofold swing in delivered platelet dose before any other variable moves, so a protocol that doesn't fix the draw volume, the anticoagulant, the g-force and duration of each spin, the resuspension volume and the maximum hold time isn't a protocol at all.
Which contamination and sterility failures arise from open-system processing?
Autologous doesn't mean sterile, and that one misconception drives most of the sloppiness in this area. Blood leaves the vein sterile and stays that way only while the path from vein to scalp stays sealed, so every unsealed rim you decant across is an opening for skin flora into a warm, protein-rich medium you're about to inject.
| Exposure Point | Closed System | Open Workflow |
|---|---|---|
| Transfer path | Sealed and integrated | Decanted across an unsealed rim |
| Room air contact | None | Every decant and draw-up |
| Likely contaminant | Rare | Patient or operator skin flora |
| Particulates | Minimal | Gel shards, rubber cores, fibrin clumps |
The open-system failure with real regulatory teeth isn't microbial at all, it's administrative, because two patients processed concurrently on one bench with unlabelled tubes is a genuine cross-transfusion risk, which is why one patient's blood belongs on the bench at a time and labels go on at the moment of draw.
What clinical signs suggest a patient is being under-dosed rather than being a non-responder?
Pattern is the tell. Genuine non-response scatters, because what limits it is specific to the patient, so a correctly run service gives you a spread where some people improve clearly, several change modestly and a minority show nothing. When almost everyone lands flat, it isn't your patients, it's a process problem wearing a biology costume.
- Flat cohort: An unbroken run of no-change results points at process, not biology.
- Timeline: Adequately dosed courses most commonly show change from around month three.
- Fading early response: Brief shedding reduction that stops with nothing following it.
- Genuine predictors: Advanced miniaturisation, scarring alopecia, untreated thyroid or iron deficiency.
Improvement after an adequately dosed course is most commonly reported from around the third month, with the reviewed studies measuring hair density gains at three and six months, so a whole cohort still flat at month four is a process finding rather than a run of non-responders.
How does variable leukocyte and red cell content affect scalp response and downtime?
White cells are the most consequential variable almost nobody measures. Neutrophils release reactive oxygen species and proinflammatory cytokines and raise matrix metalloproteinase levels in a compartment already full of growth factors, which is useful in some tendon and wound work and much less obviously useful in a scalp where downtime is the currency you're spending.
Recorded adverse effects of scalp injection are generally limited to transient pain, mild erythema and swelling at the application site, and no published figure exists for how much longer a red-tinged or neutrophil-heavy preparation keeps a patient uncomfortable, so an uncontrolled cell fraction leaves you unable to predict your own procedure.
What record-keeping gaps make a disappointing outcome impossible to diagnose afterwards?
The moment a patient tells you it didn't work, you're either holding a reconstructable record or an opinion. Nothing on that record takes more than a minute to capture, and every item on it is a candidate explanation for a flat result, which is exactly what makes the gaps so expensive.
- Lot and expiry: The only way to tie a bad quarter to a batch or a substitution.
- Injection map: Forty points at the vertex versus twenty at the hairline is a real dose difference.
- Spin record: G-force and duration for each pass, plus the final concentrate volume.
- Baseline photography: Without it neither side can show change, so the argument resolves on assertion.
A reconstructable session record carries the date, the operator, the device lot and expiry, the blood volume drawn, the anticoagulant, the g-force and duration of each spin, the final concentrate volume, any activation, the injection depth and point count, and the interval since the last session, and it is the first thing an insurer or a regulator asks to see.
What regulatory and liability exposure follows from undocumented or off-label device use?
Regulators generally look at three separate questions, and most clinics answer only the first. Your clearance was probably written narrowly, your product category turns on what you added to the blood, and your advertising is policed by people who don't need a patient injury to act. All three vary by country and often by state or province, so read the actual instructions for use and the actual local rules rather than borrowing a colleague's assumptions.
- The device: Clearances for blood separation systems are usually written narrowly for a stated purpose, so scalp use often sits outside that literal wording even where the practice is entirely lawful.
- The product: Adding anything beyond an anticoagulant and an activating agent, culturing, or storing between visits can move the material out of the simple autologous category and into a regulated biologic.
- The claim: Guaranteed regrowth language, before-and-after imagery and success percentages you never measured are policed by advertising and consumer protection authorities.
- Who does the work: Delegation rules for venepuncture, processing and injection differ by jurisdiction, and a reserved act performed by a technician is a licensing matter regardless of outcome.
Clearances for blood separation systems are usually written narrowly, often covering preparation of platelet-rich plasma from a small volume of the patient's own blood for a specific stated purpose, so scalp use frequently sits outside that wording and your consent has to say so in plain language alongside variable response and the expectation of multiple sessions.
How do wasted tubes, repeat sessions and refunds show up in the real cost per case?
Kit price is the least interesting number in this calculation. Your real cost per session is the consumable plus your chair time plus a share of the room, the centrifuge and the admin, and in most practices the labour term dwarfs the device. Once yield enters the comparison, the cheaper option can invert outright.
| Cost Line | Cheaper, Lower-Yield Kit | Matched Kit |
|---|---|---|
| Kit price | Forty percent less | Baseline |
| Platelet recovery | About half as many | Full stated yield |
| Cost per billion platelets | Roughly twenty percent higher | Baseline |
| Knock-on waste | Weak results invite goodwill re-treatments | Fewer slots given away |
A kit costing forty percent less that recovers half as many platelets delivers roughly twenty percent more cost per billion platelets injected, and since dose is what produces the response, you're paying a higher effective price for a weaker treatment.
What happens to patient retention across a multi-session course when results are erratic?
Attrition has a predictable shape. Platelet therapy for hair sells as a series, commonly three to four sessions at roughly monthly intervals followed by maintenance every three to six months, and the visible payoff sits just past the point where people decide whether to carry on.
- Session two lands flat: No felt response and no drop in shedding.
- Session three never books: A meaningful share of patients quietly stop there.
- The course under-delivers: A partially treated patient gets exactly the flat result they feared.
- The chart says non-responder: The treatment takes the blame the process earned.
- The review stays indexed: It's read for years by the high-intent prospect comparing providers.
A hair platelet course is commonly sold as three to four sessions at roughly monthly intervals followed by maintenance every three to six months, so a patient who stops after session two guarantees the flat outcome that then gets recorded as non-response.
